Tafasitamab

Status:

Do Not Prescribe (DNP)

Decision Date:

June 2023

Comments

DNP: NICETA883- Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. NHSE commissioned. 

search again